Luminex Corporation (LMNX) Releases Earnings Results, Beats Expectations By $0.13 EPS

Luminex Corporation (LMNX) reported quarterly earnings results on Monday, May-2-2016. The company said it had a profit of $0.29 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.13. Analysts had a consensus of $0.16. The company posted revenue of $63.00 million in the period, compared to analysts expectations of $60.98 million. The company’s revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.23 EPS.

Luminex Corporation opened for trading at $20.44 and hit $20.67 on the upside on Wednesday, eventually ending the session at $20.58, with a gain of 0.39% or 0.08 points. The heightened volatility saw the trading volume jump to 1,55,564 shares. Company has a market cap of $888 M.

In a different news, on Jan 6, 2016, G Walter Ii Loewenbaum (director) sold 41,056 shares at $20.53 per share price. According to the SEC, on Dec 18, 2015, Russell W Bradley (SVP, Corp Dev & CMO) sold 6,514 shares at $22.75 per share price. On May 29, 2015, Nachum Shamir (CEO) purchased 6,000 shares at $16.73 per share price, according to the Form-4 filing with the securities and exchange commission.

Luminex Corporation is a developer manufacturer and marketer of biological testing technologies with applications throughout the clinical diagnostic and life science industries. The Company’s xMAP (Multi-Analyte Profiling) technology is being used within fields of drug discovery and development and for clinical diagnostics genetic analysis bio-defense food safety and biomedical research. In addition to its xMAP technology the Company has its MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The instruments in the Company’s xMAP line include LX200 system which offers 100-plex testing; FLEXMAP 3D system which is a 500-plex testing system; and MAGPIX system which provides 50-plex testing at a lower cost using imaging rather than flow cytometry. The Company’s products include Instruments Consumables Software and Assay Product Families.

Luminex Corporation

Leave a Reply

Luminex Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Luminex Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.